(redirected from P-glycoprotein)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to P-glycoprotein: ABCB1
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to glycoprotein

References in periodicals archive ?
Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.
Expression of P-glycoprotein and anionic glutathione S-transferase in recurrent lymphomas: the possible role of Ebstein Barr virus immunophenotypes and other predisposing factors.
Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
Proposed mechanisms include increased bioavailability of digoxin with gastric acid suppression, phenotypic or age-related alterations in metabolism resulting in slow or delayed metabolism of omeprazole or digoxin, inhibition of the p-glycoprotein system or a previously unexplained interaction.
Toremifene CYP3A4 Active Induction: [up arrow] efficacy Inhibition: [up arrow] risk of adverse effects Glucocorticoids CYP3A4 Inhibitors: CYP3A4 inducer [up arrow] risk corticosteroid -related toxicity Inducers: [down arrow] efficacy Reduces efficacy of CYP3A4 substrates Table IV Anticancer drugs that are p-glycoprotein substrates Clilorambucil Etoposide Cisplatin Methylprednisolone Dactinomycin Mitoxantrone Daunorubicin Paclitaxel Dexamethasone Tamoxifen Docetaxel Vinblastine Doxorubicin Vincristine
To investigate whether silent mutations play a role, Gottesman and his colleagues worked with different varieties of the gene called MDR1, which makes P-glycoprotein.
The recently approved echinocandin micafungin (Mycamine) is not a substrate or inhibitor for P-glycoprotein, a trans-membrane efflux pump in the liver, intestine, kidneys, and blood-brain barrier.
Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein.
P-glycoprotein (P-gp) overexpression is the major mechanism by which cancer cells acquire multidrug resistance (MDR) rendering conventional chemotherapy regimens ineffective.
It is generally believed that P-glycoprotein and related molecules are responsible for cancer cells or microorganisms pumping out the drugs that constitute many of the conventional chemotherapy agents, giving rise to multidrug resistance, or MDR, which results in a cross-resistance to many drugs affected by MDR.
While the exact reason for this interaction with cyclosporine is unclear, previous research has indicated that the herb appears to boost the activity of a "drug transporter" in cells called P-glycoprotein.
They have identified the structure of a pump molecule called P-glycoprotein, which is present in small amounts in healthy tissue where it plays a role in normal metabolic processes.
An overview of the complex but potentially important research on P-glycoprotein (P-gp), a molecular "pump" that can remove drugs from cells, preventing the drugs from working.
The oral availability of PTX is seriously hampered by drug efflux through P-glycoprotein (P-gp) and drug metabolism via cytochrome P450 (CYP) 3A (Hendrikx et al.